Substitutions in the beta subunits of sickle-cell hemoglobin improve oxidative stability and increase the delay time of sickle-cell fiber formation. Shet AS, Mendelsohn L, Harper J, Ostrowski D, Henry ER, Gwaabe E, Nichols J, Alayash AI, Eaton WA, Thein SL Voxelotor treatment of a patient with sickle cell disease and very severe anemia. Redox states of hemoglobin determine left ventricle pressure recovery and activity of mitochondrial complex IV in hypoxic rat hearts.Įdmondson M, Jana S, Meng F, Strader MB, Baek JH, Gao Y, Buehler PW, Alayash AIĪntisickling drugs targeting betaCys93 reduce iron oxidation and oxidative changes in sickle cell hemoglobin. Mechanisms of toxicity and modulation of hemoglobin-based oxygen carriers (HBOCs). Our mission-oriented laboratory research on the safety and efficacy evaluation of HBOCs has been published in major peer-reviewed journals and presented at national and international meetings. More recently we discovered functions of Hp in controlling blood pressure effects that not only represent a new paradigm for blood-substitutes research but might also have clinical use in the treatment of hemolytic anemias. Our major contributions to the field of HBOCs include, 1) defining toxicological pathways that arise from and are driven by the heme prosthetic group of the molecule 2) designing protective molecular strategies to suppress or control Hb oxidative side reactions 3) correlating Hb and its various redox and oxygenation states with the expression of hypoxia-inducible factor (HIF-1alpha), an "oxygen sensor," and other hypoxia-sensitive genes in a model of exchange transfusion and 4) defining the site-specific nature of the interaction between haptoglobin (Hp) and Hb, which is the basis of the Hb clearance pathway in human macrophages. The basis of HBOC toxicity is poorly understood since most research done by industry is proprietary, and there is only minimal exchange of information among investigators occurs. We are also investigating several potential molecular interventions for directly or indirectly overcoming Hb toxicity in vitro and in vivo. Specifically, we study the potential contributions of Hb-based reactive intermediates to oxidative and signaling cascades both in vitro and in vivo. The focus of research of the Biochemistry of Hemoglobin (Hb)-based Substitutes Section is on the structural-functional characterization of modified Hb in relation to its redox (reduction-oxidation) chemistry and toxicity. Several major manufacturers recently terminated their clinical trials in the US because of significantly increased adverse events in patients who were infused with currently available investigational HBOC products. However, they also raise a number of concerns, including toxicity. HBOCs have many potential advantages over human blood, including availability compatibility, and long-term storage. Our work is contributing to the regulatory and research efforts of CBER to support development of safe and effective products that improve public health in the US and worldwide. These findings suggest that it might be possible to design safer HBOCs, since Hb bound to haptoglobin can still carry oxygen and release it to tissues. Haptoglobin had this beneficial effect either when it was directly infused into animals or when animals were treated with a drug that increased the body's production of haptoglobin. We previously published results of a study in animal models showing that a molecule called haptoglobin found in blood can bind to Hb, preventing it from causing damage.
#Blood and iron wiki free
We are studying how free Hb causes its toxic effects and are developing ways to prevent these effects. Our laboratory is trying to overcome the problem of Hb toxicity in order to enable industry to manufacture safe and effective HBOCs. Therefore, FDA has not approved any HBOCs for use in the United States, and the regulatory agencies of most other countries also have not approved HBOCs. This cell free Hb can cause high blood pressure Hb can also escape the blood vessels and damage the kidneys and other organs. However, because the Hb used for HBOCs is not inside red blood cells it tends to accumulate to toxic levels in the blood. HBOCs use the natural oxygen-carrying molecule called hemoglobin (Hb) to carry oxygen throughout the body. One type of artificial blood substitute that scientists have studied extensively is called a "hemoglobin-based oxygen carrier" (HBOC). The development of a safe and effective blood substitute would greatly improve the emergency treatment of accident victims and wounded soldiers, as well as patients undergoing cardiac surgery, especially when whole blood is in short supply.
Office / Division / Lab: OBRR / DBCD / LBVB